Activated mTORC1 signaling: The common driving force of type 2 diabetes and hidradenitis suppurativa
Authors:
- 1 May 2018
- journal article
- letter
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 78 (5) , e121-E121
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Hidradenitis suppurativa and diabetes mellitus: A systematic review and meta-analysisJournal of the American Academy of Dermatology, 2018
- The Magnitude of mTORC1 Signalling May Predict the Response to Isotretinoin Treatment in Patients with Hidradenitis SuppurativaDermatology, 2017
- Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agentsJournal of the American Academy of Dermatology, 2017
- Interleukin‐17 as a factor linking the pathogenesis of psoriasis with metabolic disordersInternational Journal of Dermatology, 2016
- Mammalian target of rapamycin, insulin resistance and hidradenitis suppurativa: a possible metabolic loopJournal of the European Academy of Dermatology and Venereology, 2015
- TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologistsCell Death & Disease, 2013